Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M

Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best NASDAQ stocks under $5 to buy right now. On May 5, Compass Therapeutics reported a Q1 2026 net loss of $18.3 million, or $0.10 per share. R&D expenses rose to $13.4 million, while G&A expenses climbed 41% to $6.9 million due to stock compensation and $1.0 million in pre-commercialization costs. The company ended the quarter with $195 million in cash and marketable securities, providing an anticipated capital runway into 2028.

Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M

Pixabay/Public domain

The company is preparing for a BLA submission and an FDA meeting later this year for tovecimig, which recently received Orphan Drug Designation for biliary tract cancer/BTC. In a Phase 2/3 study, the tovecimig combination met its primary endpoint with a 17.1% overall response rate versus 5.3% for paclitaxel alone. It also significantly improved median progression-free survival to 4.7 months compared to 2.6 months for the control group.

Compass Therapeutics Inc. (NASDAQ:CMPX) has also initiated cohort expansions for CTX-8371 across breast, lung, and lymphoma indications, with initial data scheduled for presentation at ASCO 2026. Additionally, a Phase 1 study has commenced for CTX-10726 in solid tumors, with initial data expected in Q4 2026. Finally, a Phase 2 trial for the company’s CD137 agonist, CTX-471, is on track to begin in H2 2026.

Compass Therapeutics Inc. (NASDAQ:CMPX) is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics for the treatment of various human diseases in the US.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.